Vertex initiated at Guggenheim

Vertex resumed with a Neutral at Guggenheim. Guggenheim analyst Whitney Ijem resumed coverage of Vertex Pharmaceuticals with a Neutral rating. The analyst thinks a successful launch of the triple combo is priced into the shares and that the risk/reward on progress is “skewed to the downside at this stage.” Further, she thinks any competitive cystic fibrosis updates could be an overhang and the “what’s next” question will become more important.
https://thefly.com/landingPageNews.php?id=2838247